Novo Nordisk A/S (NYSE:NVO) Shares Sold by Prime Capital Investment Advisors LLC

Prime Capital Investment Advisors LLC reduced its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 12.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 64,191 shares of the company's stock after selling 9,497 shares during the quarter. Prime Capital Investment Advisors LLC's holdings in Novo Nordisk A/S were worth $7,643,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC increased its stake in shares of Novo Nordisk A/S by 14.8% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company's stock worth $34,463,000 after purchasing an additional 37,346 shares in the last quarter. Private Wealth Partners LLC boosted its holdings in Novo Nordisk A/S by 155.1% in the 3rd quarter. Private Wealth Partners LLC now owns 33,203 shares of the company's stock worth $3,953,000 after buying an additional 20,188 shares during the last quarter. Channel Wealth LLC increased its stake in Novo Nordisk A/S by 15.6% during the 3rd quarter. Channel Wealth LLC now owns 57,353 shares of the company's stock worth $6,829,000 after buying an additional 7,756 shares in the last quarter. Buckingham Capital Management Inc. acquired a new position in shares of Novo Nordisk A/S during the third quarter valued at approximately $3,874,000. Finally, Independence Bank of Kentucky lifted its position in shares of Novo Nordisk A/S by 192.7% in the third quarter. Independence Bank of Kentucky now owns 11,490 shares of the company's stock valued at $1,368,000 after acquiring an additional 7,565 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Down 0.1 %

Novo Nordisk A/S stock traded down $0.14 during midday trading on Wednesday, hitting $106.93. 3,156,511 shares of the stock were exchanged, compared to its average volume of 4,440,904. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The stock's 50-day simple moving average is $120.23 and its 200 day simple moving average is $130.08. Novo Nordisk A/S has a fifty-two week low of $94.73 and a fifty-two week high of $148.15. The stock has a market capitalization of $479.83 billion, a price-to-earnings ratio of 34.60, a PEG ratio of 1.29 and a beta of 0.42.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on NVO. BMO Capital Markets reduced their price objective on Novo Nordisk A/S from $160.00 to $156.00 and set an "outperform" rating for the company in a research note on Thursday, October 17th. StockNews.com raised shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research note on Friday, November 1st. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $144.50.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.